Orexo AB (publ) (ORX.ST)
Stockholm · SEK · Healthcare · Drug Manufacturers - Specialty & Generic
SEK 4.88 (-4.50%) as of
Key statistics
- Forward P/E
- -0.67
- EPS (TTM)
- -12.6400
- Dividend yield
- 0.00%
- 52-week range
- 4.7800 – 36.0000
- Beta
- 0.86
- Revenue (TTM)
- 12.5M
- Profit margin
- 3,152.80%
- Analyst target
- SEK 26.50
- Volume
- 68.42k
About Orexo AB (publ)
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Uppsala, Sweden
- Employees
- 55
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.